Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma
At ASH 2024, Frida Bugge Askeland from the Oslo Myeloma Center presented an abstract demonstrating the feasibility of replacing steroids in the treatment of transplant-ineligible myeloma patients. In this study, dexamethasone was removed early in the treatment regimen and substituted with bortezomib, creating a novel combination of isatuximab, bortezomib, and lenalidomide. In this interview, Frida Bugge Askeland discusses the clinical outcomes and implications of this adjusted steroid approach.
